{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:20:06Z","timestamp":1764919206999,"version":"3.46.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114-2811-B-A49A-004","NSTC 112-2314-B-A49-083-MY3"],"award-info":[{"award-number":["NSTC 114-2811-B-A49A-004","NSTC 112-2314-B-A49-083-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021037","name":"Taipei City Hospital","doi-asserted-by":"publisher","award":["TPCH-113-37"],"award-info":[{"award-number":["TPCH-113-37"]}],"id":[{"id":"10.13039\/100021037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114C-013"],"award-info":[{"award-number":["V114C-013"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dr. Morris Chang","award":["ABMRD002"],"award-info":[{"award-number":["ABMRD002"]}]},{"DOI":"10.13039\/100031316","name":"Melissa Lee Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013179","name":"Teh-Tzer Study Group for Human Medical Research Foundation of Taiwan","doi-asserted-by":"publisher","award":["B1131020"],"award-info":[{"award-number":["B1131020"]}],"id":[{"id":"10.13039\/501100013179","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Szu-Yuan Research Foundation of Internal Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01874-x","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:34:13Z","timestamp":1761892453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting SET to counteract Lyn activation demonstrates anti-cancer potential in diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Ji-Lin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yi","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Teng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Lun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Ya","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Shen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"1874_CR1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74\u201387.","journal-title":"Pathology"},{"key":"1874_CR2","doi-asserted-by":"crossref","first-page":"FSO322","DOI":"10.4155\/fsoa-2018-0049","volume":"4","author":"A Galaznik","year":"2018","unstructured":"Galaznik A, Huelin R, Stokes M, Guo Y, Hoog M, Bhagnani T, et al. Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Future Sci OA. 2018;4:FSO322.","journal-title":"Future Sci OA"},{"key":"1874_CR3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22\u201332.","journal-title":"Blood"},{"key":"1874_CR4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1158\/2159-8290.CD-20-0174","volume":"10","author":"D Ennishi","year":"2020","unstructured":"Ennishi D, Hsi ED, Steidl C, Scott DW. Toward a new molecular taxonomy of diffuse large B-cell lymphoma. Cancer Discov. 2020;10:1267\u201381.","journal-title":"Cancer Discov"},{"key":"1874_CR5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","volume":"52","author":"RM Young","year":"2015","unstructured":"Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52:77\u201385.","journal-title":"Semin Hematol"},{"key":"1874_CR6","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2017-10-809210","volume":"131","author":"E Battistello","year":"2018","unstructured":"Battistello E, Katanayeva N, Dheilly E, Tavernari D, Donaldson MC, Bonsignore L, et al. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma. Blood. 2018;131:2345\u201356.","journal-title":"Blood"},{"key":"1874_CR7","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/ccr3.1253","volume":"5","author":"Y Takeyasu","year":"2017","unstructured":"Takeyasu Y, Satake A, Azuma Y, Tsubokura Y, Yoshimura H, Hotta M, et al. Tyrosine kinase inhibitor and rituximab-CHOP treatment for concurrent chronic myeloid leukemia and non-Hodgkin lymphoma: a case report. Clin Case Rep. 2017;5:2047\u201350.","journal-title":"Clin Case Rep"},{"key":"1874_CR8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2016.09.007","volume":"30","author":"PH Nguyen","year":"2016","unstructured":"Nguyen PH, Fedorchenko O, Rosen N, Koch M, Barthel R, Winarski T, et al. Lyn kinase in the tumor microenvironment is essential for the progression of chronic lymphocytic leukemia. Cancer Cell. 2016;30:610\u201322.","journal-title":"Cancer Cell"},{"key":"1874_CR9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1478-811X-10-21","volume":"10","author":"E Ingley","year":"2012","unstructured":"Ingley E. Functions of the Lyn tyrosine kinase in health and disease. Cell Commun Signal. 2012;10:21.","journal-title":"Cell Commun Signal"},{"key":"1874_CR10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.molimm.2020.12.028","volume":"131","author":"Y Sun","year":"2021","unstructured":"Sun Y, Yang Y, Zhao Y, Li X, Zhang Y, Liu Z. The role of the tyrosine kinase Lyn in allergy and cancer. Mol Immunol. 2021;131:121\u20136.","journal-title":"Mol Immunol"},{"key":"1874_CR11","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab152","author":"BFt Brian","year":"2021","unstructured":"Brian BFt, Freedman TS. The src-family kinase Lyn in immunoreceptor signaling. Endocrinology. 2021;162:bqab152. https:\/\/doi.org\/10.1210\/endocr\/bqab152.","journal-title":"Endocrinology"},{"key":"1874_CR12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1074-7613(01)00208-4","volume":"15","author":"KW Harder","year":"2001","unstructured":"Harder KW, Parsons LM, Armes J, Evans N, Kountouri N, Clark R, et al. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity. 2001;15:603\u201315.","journal-title":"Immunity"},{"key":"1874_CR13","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1084\/jem.20020515","volume":"196","author":"ML Hibbs","year":"2002","unstructured":"Hibbs ML, Harder KW, Armes J, Kountouri N, Quilici C, Casagranda F, et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med. 2002;196:1593\u2013604.","journal-title":"J Exp Med"},{"key":"1874_CR14","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2007-05-090985","volume":"111","author":"S Tauzin","year":"2008","unstructured":"Tauzin S, Ding H, Khatib K, Ahmad I, Burdevet D, van Echten-Deckert G, et al. Oncogenic association of the Cbp\/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts. Blood. 2008;111:2310\u201320.","journal-title":"Blood"},{"key":"1874_CR15","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3324\/haematol.2016.155747","volume":"102","author":"E Tibaldi","year":"2017","unstructured":"Tibaldi E, Pagano MA, Frezzato F, Trimarco V, Facco M, Zagotto G, et al. Targeted activation of the SHP-1\/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells. Haematologica. 2017;102:1401\u201312.","journal-title":"Haematologica"},{"key":"1874_CR16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.molmed.2008.02.001","volume":"14","author":"J Westermarck","year":"2008","unstructured":"Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008;14:152\u201360.","journal-title":"Trends Mol Med"},{"key":"1874_CR17","doi-asserted-by":"crossref","first-page":"11059","DOI":"10.1074\/jbc.271.19.11059","volume":"271","author":"M Li","year":"1996","unstructured":"Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996;271:11059\u201362.","journal-title":"J Biol Chem"},{"key":"1874_CR18","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2011-04-351072","volume":"118","author":"DJ Christensen","year":"2011","unstructured":"Christensen DJ, Chen Y, Oddo J, Matta KM, Neil J, Davis ED, et al. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood. 2011;118:4150\u20138.","journal-title":"Blood"},{"key":"1874_CR19","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/onc.2010.622","volume":"30","author":"CH Switzer","year":"2011","unstructured":"Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET\/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011;30:2504\u201313.","journal-title":"Oncogene"},{"key":"1874_CR20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2006-10-053884","volume":"111","author":"Q Liu","year":"2008","unstructured":"Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia\/lymphoma. Blood. 2008;111:275\u201384.","journal-title":"Blood"},{"key":"1874_CR21","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1038\/onc.2016.21","volume":"35","author":"MH Hung","year":"2016","unstructured":"Hung MH, Chen YL, Chu PY, Shih CT, Yu HC, Tai WT, et al. Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential. Oncogene. 2016;35:4891\u2013902.","journal-title":"Oncogene"},{"key":"1874_CR22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"1874_CR23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjh.14620","volume":"177","author":"CY Liu","year":"2017","unstructured":"Liu CY, Hsieh FS, Chu PY, Tsai WC, Huang CT, Yu YB, et al. Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1\/KIAA1524 (Elk-1\/CIP2A) and activating PP2A not related to proteasome inhibition. Br J Haematol. 2017;177:726\u201340.","journal-title":"Br J Haematol"},{"key":"1874_CR24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s10020-022-00518-0","volume":"28","author":"JL Chen","year":"2022","unstructured":"Chen JL, Chu PY, Huang CT, Huang TT, Wang WL, Lee YH, et al. Interfering B cell receptor signaling via SHP-1\/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma. Mol Med. 2022;28:93.","journal-title":"Mol Med"},{"key":"1874_CR25","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.ebiom.2020.102717","volume":"54","author":"TT Huang","year":"2020","unstructured":"Huang TT, Tseng LM, Chen JL, Chu PY, Lee CH, Huang CT, et al. Kynurenine 3-monooxygenase upregulates pluripotent genes through beta-catenin and promotes triple-negative breast cancer progression. EBioMedicine. 2020;54:102717.","journal-title":"EBioMedicine"},{"key":"1874_CR26","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2007-09-110601","volume":"111","author":"A Ruiz-Vela","year":"2008","unstructured":"Ruiz-Vela A, Aggarwal M, de la Cueva P, Treda C, Herreros B, Martin-Perez D, et al. Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways. Blood. 2008;111:1665\u201376.","journal-title":"Blood"},{"key":"1874_CR27","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","volume":"105","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105:13520\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1874_CR28","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.","journal-title":"Nucleic Acids Res"},{"key":"1874_CR29","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1874_CR30","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739\u201340.","journal-title":"Bioinformatics"},{"key":"1874_CR31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1080\/10428194.2024.2446613","volume":"66","author":"W Harris","year":"2025","unstructured":"Harris W, Cao Y, Morschhauser F, Salles G, Jiang Y, Bottos A, et al. GneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles. Leuk Lymphoma. 2025;66:898\u2013905.","journal-title":"Leuk Lymphoma"},{"issue":"551\u2013568","key":"1874_CR32","first-page":"e514","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell Lymphoma with Therapeutic implications. Cancer Cell. 2020;37(551\u2013568):e514.","journal-title":"Cancer Cell"},{"key":"1874_CR33","doi-asserted-by":"crossref","first-page":"113652","DOI":"10.1016\/j.yexcr.2023.113652","volume":"429","author":"LM Tseng","year":"2023","unstructured":"Tseng LM, Lau KY, Chen JL, Chu PY, Huang TT, Lee CH, et al. Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model. Exp Cell Res. 2023;429:113652.","journal-title":"Exp Cell Res"},{"key":"1874_CR34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell. 2005;8:355\u201368.","journal-title":"Cancer Cell"},{"key":"1874_CR35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.immuni.2011.04.010","volume":"34","author":"W Xiao","year":"2011","unstructured":"Xiao W, Kashiwakura J, Hong H, Yasudo H, Ando T, Maeda-Yamamoto M, et al. Phospholipase C-beta3 regulates FcvarepsilonRI-mediated mast cell activation by recruiting the protein phosphatase SHP-1. Immunity. 2011;34:893\u2013904.","journal-title":"Immunity"},{"key":"1874_CR36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2013.02.036","volume":"335","author":"P Seshacharyulu","year":"2013","unstructured":"Seshacharyulu P, Pandey P, Datta K, Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013;335:9\u201318.","journal-title":"Cancer Lett"},{"key":"1874_CR37","doi-asserted-by":"crossref","first-page":"40475","DOI":"10.1074\/jbc.M402970200","volume":"279","author":"ML Jones","year":"2004","unstructured":"Jones ML, Craik JD, Gibbins JM, Poole AW. Regulation of SHP-1 tyrosine phosphatase in human platelets by serine phosphorylation at its C terminus. J Biol Chem. 2004;279:40475\u201383.","journal-title":"J Biol Chem"},{"key":"1874_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.12.032","author":"CY Liu","year":"2019","unstructured":"Liu CY, Huang TT, Chen YT, Chen JL, Chu PY, Huang CT, et al. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression. EBioMedicine. 2019;40:263\u2013275. https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.032.","journal-title":"EBioMedicine"},{"key":"1874_CR39","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1078-0432.CCR-14-0166","volume":"20","author":"P Neviani","year":"2014","unstructured":"Neviani P, Perrotti D. Setting OP449 into the PP2A-activating drug family. Clin Cancer Res. 2014;20:2026\u20138.","journal-title":"Clin Cancer Res"},{"key":"1874_CR40","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1182\/blood-2014-12-619155","volume":"125","author":"F Zonta","year":"2015","unstructured":"Zonta F, Pagano MA, Trentin L, Tibaldi E, Frezzato F, Trimarco V, et al. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood. 2015;125:3747\u201355.","journal-title":"Blood"},{"key":"1874_CR41","doi-asserted-by":"crossref","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma, Cell. 2017;171:481-94 e15","DOI":"10.1016\/j.cell.2017.09.027"},{"key":"1874_CR42","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"1874_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010185","author":"N Coccaro","year":"2020","unstructured":"Coccaro N, Anelli L, Zagaria A, Perrone T, Specchia G, Albano F. Molecular complexity of diffuse large B-cell lymphoma: can it be a roadmap for precision medicine? Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12010185.","journal-title":"Cancers (Basel)"},{"key":"1874_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2017.1336226","author":"MH Hung","year":"2017","unstructured":"Hung MH, Chen KF. Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer. Expert Opin Ther Targets. 2017. https:\/\/doi.org\/10.1080\/14728222.2017.1336226.","journal-title":"Expert Opin Ther Targets"},{"key":"1874_CR45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","volume":"130","author":"MR Junttila","year":"2007","unstructured":"Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51\u201362.","journal-title":"Cell"},{"key":"1874_CR46","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/onc.2009.7","volume":"28","author":"AK Samanta","year":"2009","unstructured":"Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 2009;28:1669\u201381.","journal-title":"Oncogene"},{"key":"1874_CR47","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.3892\/or.2013.2765","volume":"30","author":"L Zhang","year":"2013","unstructured":"Zhang L, Wang HD, Ji XJ, Cong ZX, Zhu JH, Zhou Y. FTY720 for cancer therapy (review). Oncol Rep. 2013;30:2571\u20138.","journal-title":"Oncol Rep"},{"key":"1874_CR48","doi-asserted-by":"crossref","first-page":"638","DOI":"10.18632\/oncotarget.6313","volume":"7","author":"MH Hung","year":"2016","unstructured":"Hung MH, Wang CY, Chen YL, Chu PY, Hsiao YJ, Tai WT, et al. Set antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A. Oncotarget. 2016;7:638\u201355.","journal-title":"Oncotarget"},{"key":"1874_CR49","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1078-0432.CCR-13-2575","volume":"20","author":"A Agarwal","year":"2014","unstructured":"Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res. 2014;20:2092\u2013103.","journal-title":"Clin Cancer Res"},{"key":"1874_CR50","first-page":"1251","volume":"22","author":"ZZ Chong","year":"2007","unstructured":"Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007;22:1251\u201367.","journal-title":"Histol Histopathol"},{"key":"1874_CR51","doi-asserted-by":"crossref","first-page":"26648","DOI":"10.1074\/jbc.M100997200","volume":"276","author":"T Adachi","year":"2001","unstructured":"Adachi T, Wienands J, Wakabayashi C, Yakura H, Reth M, Tsubata T. SHP-1 requires inhibitory co-receptors to down-modulate B cell antigen receptor-mediated phosphorylation of cellular substrates. J Biol Chem. 2001;276:26648\u201355.","journal-title":"J Biol Chem"},{"key":"1874_CR52","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/eji.200425465","volume":"35","author":"K Mizuno","year":"2005","unstructured":"Mizuno K, Tagawa Y, Watanabe N, Ogimoto M, Yakura H. SLP-76 is recruited to CD22 and dephosphorylated by SHP-1, thereby regulating B cell receptor-induced c-Jun N-terminal kinase activation. Eur J Immunol. 2005;35:644\u201354.","journal-title":"Eur J Immunol"},{"key":"1874_CR53","doi-asserted-by":"crossref","first-page":"44703","DOI":"10.18632\/oncotarget.6300","volume":"6","author":"C Demosthenous","year":"2015","unstructured":"Demosthenous C, Han JJ, Hu G, Stenson M, Gupta M. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma. Oncotarget. 2015;6:44703\u201313.","journal-title":"Oncotarget"},{"key":"1874_CR54","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1097\/01.LAB.0000106503.65258.2B","volume":"83","author":"M Koyama","year":"2003","unstructured":"Koyama M, Oka T, Ouchida M, Nakatani Y, Nishiuchi R, Yoshino T, et al. Activated proliferation of B-cell lymphomas\/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest. 2003;83:1849\u201358.","journal-title":"Lab Invest"},{"key":"1874_CR55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/leu.2013.251","volume":"28","author":"TE Witzig","year":"2014","unstructured":"Witzig TE, Hu G, Offer SM, Wellik LE, Han JJ, Stenson MJ, et al. Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy. Leukemia. 2014;28:147\u201354.","journal-title":"Leukemia"},{"key":"1874_CR56","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","volume":"27","author":"K Valla","year":"2018","unstructured":"Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2018;27:513\u201322.","journal-title":"Expert Opin Investig Drugs"},{"key":"1874_CR57","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fimmu.2018.00401","volume":"9","author":"EJ Brodie","year":"2018","unstructured":"Brodie EJ, Infantino S, Low MSY, Tarlinton DM. Lyn, lupus, and (B) lymphocytes, a lesson on the critical balance of kinase signaling in immunity. Front Immunol. 2018;9:401.","journal-title":"Front Immunol"},{"key":"1874_CR58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V98.2.343","volume":"98","author":"B O'Laughlin-Bunner","year":"2001","unstructured":"O\u2019Laughlin-Bunner B, Radosevic N, Taylor ML, Shivakrupa C, DeBerry DD, Metcalfe M, et al. Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood. 2001;98:343\u201350.","journal-title":"Blood"},{"key":"1874_CR59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-017-0447-6","volume":"10","author":"P Balsas","year":"2017","unstructured":"Balsas P, Esteve-Arenys A, Roldan J, Jimenez L, Rodriguez V, Valero JG, et al. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma. J Hematol Oncol. 2017;10:80.","journal-title":"J Hematol Oncol"},{"key":"1874_CR60","doi-asserted-by":"crossref","first-page":"38225","DOI":"10.18632\/oncotarget.5425","volume":"6","author":"A Kim","year":"2015","unstructured":"Kim A, Seong KM, Kang HJ, Park S, Lee SS. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance. Oncotarget. 2015;6:38225\u201338.","journal-title":"Oncotarget"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01874-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01874-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01874-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:48:49Z","timestamp":1764917329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01874-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1874"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01874-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"345"}}